[Erlotnib in the treatment of advanced non-small cell lung cancer failed to previous chemotherapy].
To investigate the efficacy and side effect of erlotnib for refractory patients with advanced non-small cell lung cancer (NSCLC) failed to previous chemotherapy. Twelve patients with chemo-refractory NSCLC were enrolled into this study. Erlotnib was administered at a dose of 150 mg orally once a day for a month. The assessment was carried out every month by intensive clinical observation and monthly CT scan until disease progression or intolerable toxicity occurred. All the 12 patients were evaluable. The response rate including complete and partial responses (CR and PR) was 25.0% (3/12). The disease control rate including complete, partial response and stable disease (CR, PR and NC) was 58.3% (7/12). The clinical benefit rate was 41.7% (5/12). The main side effects included skin rash and diarrhea. No patient was withdrawn from the treatment due to intolerable toxicities. Erlotnib is effective and tolerable in the treatment of patients with advanced NSCLC failed to previous chemotherapy.